MARK GAUTHIER: Open Payments
NPI 1629593355 · WARWICK, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,377 in 67 payments from 10 companies in 2025. Trend: 2023 $1,771 · 2024 $1,552 · 2025 $1,377
Food & beverage: $1,377
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $459 |
| Vanda Pharmaceuticals Inc. | 15 | $320 |
| Axsome Therapeutics, Inc. | 6 | $173 |
| Alkermes, Inc. | 5 | $101 |
| E.R. Squibb & Sons, L.L.C. | 5 | $89 |
| Otsuka America Pharmaceutical, Inc. | 4 | $68 |
| Supernus Pharmaceuticals, Inc. | 3 | $53 |
| Neurocrine BioSciences, Inc. | 2 | $50 |
| Lundbeck LLC | 3 | $48 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
Products named: VRAYLAR, FANAPT, Auvelity, REXULTI, COBENFY, ARISTADA, Qelbree, INGREZZA.
Industry payments across RI — which companies pay providers there.
